Are the solutions to radiotherapy side effects on the gastrointestinal tract right at our doorstep?

Christoph Berliner1,∗

1 Department of Nuclear Medicine, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany

ARTICLE INFO

Article History:
Received 21 October 2021
Accepted 27 October 2021

Commentary

From a clinical perspective, radiotherapy is one of the most effective therapeutic swords against malignant diseases available. However, due to its tremendous efficacy, radiotherapy also causes a not insignificant and undesirable collateral damage to the healthy gastrointestinal tract. To reduce these undesirable side effects, physical process optimization with individualized radiation schedules, CT and MRI-assisted optimization of the radiation field, and stereotactic techniques are currently used. Nonetheless, adverse exposure of healthy portions of the bowel cannot be entirely avoided.

The root cause of gastrointestinal radiation toxicity is due to the high basal cell division rate and cell turnover of the healthy intestinal mucosa. This cannot be circumvented due to the mechanism of action of radiation therapy. However, acute side effects on the existing mucosal cells are compounded by a reduction in repair capacity. The current clinical and preclinical research focus is on avoiding this acute cell toxicity by protecting the existing mucosal cells. However, the damage process is currently not well understood.

In a recent study published in EBioMedicine, the damage to the tight-junctions by radiotherapy and the prevention of the damage via activation of the MT2 gene by pravastatin is highlighted by Kwak et al. [1]. To evaluate the therapeutic effects of pravastatin, Kwak et al. resorted to detailed modelling in vitro and in vivo. In particular, in vivo, they present data from a minipig model for which the hypothesis is confirmed, a prospective workup must follow; because of the ease of drug availability, the clinical impact on treated patients would be extraordinary. In the clinical context, some retrospective studies of NSCLC and prostate cancer exist showing improved (progression-free) survival for a cohort of patients with statin use [8,9]. In the context of the current results of Kwak et al, this now provides a much broader scope for interpretation. Both clinically and preclinically, exciting times are coming with new answers.

Pravastatin is known to reduce radiation toxicity to vessels and that a protective effect on vessels may improve epithelial function [2,3]. However, little is known about the direct effect on epithelial cells. Previously, Wilkinson et al. found that statins enhance tight junction formation and thus attenuate doxorubicin-induced endothelial damage [4]. Here, the direct action and upregulation of the tight junction proteins E-Cad, ZO-1, ZO-2, OCLN, and DSG2, by pravastatin is now demonstrated.

Epithelial dysfunction via disruption of the intercellular junction is well known as a root cause of radiotoxicity, but there is very limited data in this area regarding therapeutic options [5]. When we talk about tight junctions, we also have to talk about the quite complex p38 MAP kinase pathway [6,7]. Kwak et al. nicely add another component here and show that pravastatin probably inhibits p38 MAPK via phosphorylation and, in turn, this regulates tight junction proteins including ZO-1, OCLN and DSG2 in radiation-exposed epithelial cells. In the context of this pathway, an interaction of pravastatin with the transmembrane proteins MT1 and MT2 was additionally shown, which could be further narrowed down to an activation of MT2 by pravastatin via an MT2-deficient mouse and cell model by Kwak et al. However, the basic mechanism of how MT2 expression is activated remains the subject of research and may open up MT2 as another new therapeutic target for radiotherapy-induced enteropathy. However, this further signalling pathway remains to be elucidated.

The clinical implications from this new hypothesis are clear and straightforward. Statins, which include pravastatin, are widely used for other clinical indications, particularly in the older oncology patient population. A short-term retrospective workup of the hypothesis in humans is probably already possible. If the hypothesis is confirmed, a prospective workup must follow; because of the ease of drug availability, the clinical impact on treated patients would be extraordinary. In the clinical context, some retrospective studies of NSCLC and prostate cancer exist showing improved (progression-free) survival for a cohort of patients with statin use [8,9]. In the context of the current results of Kwak et al, this now provides a much broader scope for interpretation. Both clinically and preclinically, exciting times are coming with new answers.

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2021.103641.
∗ Address for correspondence: Christoph Berliner, MD, Department of Nuclear Medicine, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany
E-mail address: christoph.berliner@uk-essen.de

https://doi.org/10.1016/j.ebiom.2021.103687
2352-3964/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contributors

CB conceived and wrote this invited Commentary.

Declaration of Competing Interest

The author reports personal fees from Janssen Pharma, outside the submitted work.

Reference

[1] Kwak SY, Jang WI, Park S, Cho SS, Lee SB, Kim Y-H, Na J, et al. Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation proctitis by regulating thrombomodulin in irradiated endothelial cells. Int J Mol Sci 2020;21 https://doi.org/10.3390/ijms21051897.
[2] Wilkinson EL, Sidaway JE, Cross MJ. Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells. J Cell Physiol 2018;233:186–200 https://doi.org/10.1002/jcp.26064.
[3] Nejdfors P, Eketund M, Westrom BR, Willén R, Jeppsson B. Intestinal permeability in humans is increased after radiation therapy. Dis Colon Rectum 2000;43:1582–7 discussion 1587 https://doi.org/10.1007/BF02236743.
[4] Kostenko S, Dimitriu G, Lægreid KJ, Moens U. Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase. World J Biol Chem 2011;2:73–89 https://doi.org/10.4331/wjbc.v2.i5.73.
[5] Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11–8 https://doi.org/10.1038/sj.cr.7290257.
[6] Atkins KM, Bitterman DS, Chaunzwa TL, Williams CL, Rahman R, Kozono DE, et al. Statin use, heart radiation dose, and survival in locally advanced lung cancer. Pract Radiat Oncol 2021;11:e459–67 https://doi.org/10.1016/j.prro.2020.12.006.
[7] Gutt R, Tonlaar N, Kunnavekkaram R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653–9 https://doi.org/10.1200/JCO.2009.27.3003.